What are the typical testosterone dosing regimens for female-to-male transgender patients?

Typical Testosterone Dosing for Female-to-Male Transgender Patients

For female-to-male transgender patients, start with testosterone cypionate or enanthate 50-100 mg intramuscularly weekly, or 100-200 mg every 2 weeks, titrating to achieve mid-normal male testosterone levels (400-700 ng/dL). Subcutaneous administration at similar doses is equally effective and often preferred by patients.

Dosing Regimens

Injectable Testosterone (Most Common)

Testosterone cypionate or enanthate:

• 50-100 mg intramuscularly weekly, OR
• 100-200 mg intramuscularly every 2 weeks 1, 2

The evidence shows these doses effectively achieve masculinization with testosterone levels in the mid-normal male range (300-1,000 ng/dL, targeting 400-700 ng/dL) 3.

Subcutaneous Alternative (Increasingly Preferred)

Subcutaneous testosterone cypionate or enanthate:

• Start at 50 mg weekly subcutaneously
• Titrate to 50-150 mg weekly (median effective dose: 75-80 mg) 4

This route is particularly important because research demonstrates it achieves equivalent testosterone levels across a wide BMI range (19.0-49.9 kg/m²) with significantly better patient satisfaction—all 22 patients who switched from IM to subcutaneous injections preferred the subcutaneous route 4. Additionally, 85% achieved menstrual cessation within 6 months, averaging 2.9 months 5.

Long-Acting Testosterone Undecanoate

For patients desiring less frequent injections:

• 1000 mg intramuscularly every 12 weeks after loading doses 6, 7
• Requires initial 6-week loading dose, then individualized interval (typically 10-14 weeks)

This formulation showed effective masculinization in female-to-male patients with the convenience of quarterly injections, though it requires monitoring for hypertension 6.

Transdermal Options

Testosterone gel:

• 5-10 g daily applied to non-genital skin 1
• Adjust dose to achieve mid-normal male testosterone levels

Testosterone patches:

• 5-10 mg patches applied nightly 1

Dose-Response Considerations

The evidence reveals an important nuance: higher initial doses produce faster onset of masculinizing effects (voice deepening, facial hair, menstrual cessation) within the first month, but by 6 months, all standard doses achieve equivalent therapeutic effects 8. This means you can start conservatively at 50 mg weekly and titrate up based on patient goals and tolerance, or start at 100 mg weekly for faster initial changes—both approaches reach the same endpoint.

Monitoring Protocol

Critical monitoring schedule:

• Testosterone levels at 3-6 months, then adjust dose to maintain mid-normal range 3

  • For weekly injections: check mid-cycle
  • For biweekly injections: check midway between doses
  • Target: 400-700 ng/dL (avoiding >700 ng/dL)

• Hematocrit at baseline, 3-6 months, then annually 3, 9

  • Stop therapy if hematocrit >54% until it decreases
  • Evaluate for hypoxia/sleep apnea before restarting at reduced dose
  • Consider switching to transdermal route if erythrocytosis develops 9

• Clinical assessment at 3-6 months, then annually for desired effects and adverse reactions 3

Common Pitfalls to Avoid

1. Overdosing: The FDA label indicates doses up to 400 mg every 2-4 weeks for hypogonadal males 2, but transgender patients typically require lower doses (50-200 mg every 2 weeks) to avoid supraphysiologic levels and adverse effects.

2. Ignoring subcutaneous option: Many providers default to IM injections, but subcutaneous administration offers equivalent efficacy with markedly better patient preference and can be self-administered more easily 4.

3. Inadequate hematocrit monitoring: Testosterone therapy carries significant risk of erythrocytosis, particularly in transgender men 9. Missing this can lead to thrombotic complications.

4. Not individualizing injection intervals: While 12-week intervals work for 70% of patients on testosterone undecanoate, 23% require shorter intervals 7. Monitor trough levels and adjust accordingly.

5. Overlooking cardiovascular risk factors: Testosterone increases blood pressure, triglycerides, and LDL while decreasing HDL 9. Monitor lipids and blood pressure, especially in patients with baseline cardiovascular risk factors.

Route Selection Algorithm

Choose subcutaneous if:

• Patient prefers self-administration
• Patient has needle anxiety (less painful)
• Any BMI (effective across 19.0-49.9 kg/m²) 4

Choose intramuscular if:

• Patient prefers clinic administration
• Established on IM with good tolerance

Choose testosterone undecanoate if:

• Patient desires quarterly injections
• Reliable follow-up for monitoring
• Avoid if: history of hypertension (2/37 patients developed serious hypertension requiring discontinuation) 6

Choose transdermal if:

• Erythrocytosis develops on injectable testosterone 9
• Patient cannot tolerate injections
• More stable testosterone levels desired (less peak-trough variation)